丙戊酸作为惊厥性癫痫持续状态的辅助治疗:一项随机临床试验
该多中心、双盲、随机对照试验纳入2013至2018年法国16家医院ICU收治的244例成人惊厥性癫痫持续状态(GCSE)患者,在苯二氮䓬类加第二种抗癫痫药物(除外丙戊酸)的标准治疗基础上,分别加用丙戊酸(30 mg/kg负荷量,继以1 mg/kg/h持续12小时输注)或安慰剂(0.9%氯化钠)。主要终点第15天出院比例在丙戊酸组为61%(77例),安慰剂组为61%(72例),校正相对危险度1.04(95%CI 0.89-1.19),p=0.58,组间无差异;次要终点(癫痫控制、不良事件、第90天认知)亦无组间差异。结论认为,丙戊酸加入推荐方案耐受性良好,但未增加第15天出院患者比例。
要点
- 244例成人GCSE患者随机接受丙戊酸(30 mg/kg负荷,继以1 mg/kg/h持续12小时)或安慰剂,两组均接受苯二氮䓬类加第二种抗癫痫药物(除外丙戊酸)的标准治疗。
- 主要终点第15天出院比例:丙戊酸组77例(61%)vs 安慰剂组72例(61%),校正RR 1.04(95%CI 0.89-1.19),p=0.58,无组间差异。
- 次要终点(癫痫控制、不良事件、第90天认知)均无组间差异。
- 丙戊酸作为辅助治疗耐受性良好,但未提高第15天出院比例。
- 224例(93%)和227例(93%)在输注丙戊酸或安慰剂前已接受一线和二线抗癫痫药物。
适用人群与场景
- 2013至2018年法国16家医院ICU收治的成人GCSE患者,共244例。
- 纳入新发确诊GCSE的成人;原文未列出具体排除标准。
处置流程与药物剂量
- 所有患者接受标准治疗:苯二氮䓬类加第二种抗癫痫药物(除外丙戊酸)。
- 干预组:丙戊酸30 mg/kg负荷量,继以1 mg/kg/h持续12小时输注。
- 安慰剂组:0.9%氯化钠,以相同方式静脉推注并持续输注。
研究设计与关键结果
- 多中心、双盲、随机对照试验,纳入244例成人GCSE患者,16家法国医院,2013至2018年。
- 丙戊酸组126例(52%),安慰剂组118例(48%);两组分别有224例(93%)和227例(93%)在输注前接受一线和二线抗癫痫药物。
- 主要终点第15天出院比例:丙戊酸组77例(61%)vs 安慰剂组72例(61%),校正RR 1.04(95%CI 0.89-1.19),p=0.58。
- 次要终点(癫痫控制、不良事件、第90天认知)均无组间差异。
证据类型、等级与局限
- 证据类型:多中心、双盲、随机对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,丙戊酸加入成人GCSE推荐治疗策略耐受性良好,但未增加第15天出院患者比例。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Generalised convulsive status epilepticus (GCSE) is a medical emergency. Guidelines recommend a stepwise strategy of benzodiazepines followed by a second-line anti-seizure medicine (ASM). However, GCSE is uncontrolled in 20-40% patients and is associated with protracted hospitalisation, disability, and mortality. The objective was to determine whether valproic acid (VPA) as complementary treatment to the stepwise strategy improves the outcomes of patients with de novo established GCSE.
METHODS: This was a multicentre, double-blind, randomised controlled trial in 244 adults admitted to intensive care units for GCSE in 16 French hospitals between 2013 and 2018. Patients received standard care of benzodiazepine and a second-line ASM (except VPA). Intervention patients received a 30 mg/kg VPA loading dose, then a 1 mg/kg/h 12 h infusion, whilst the placebo group received an identical intravenous administration of 0.9% saline as a bolus and continuous infusion. Primary outcome was proportion of patients discharged from hospital by day 15. The secondary outcomes were seizure control, adverse events, and cognition at day 90.
RESULTS: A total of 126 (52%) and 118 (48%) patients were included in the VPA and placebo groups. 224 (93%) and 227 (93%) received a first-line and a second-line ASM before VPA or placebo infusion. There was no between-group difference for patients hospital-discharged at day 15 [VPA, 77 (61%) versus placebo, 72 (61%), adjusted relative risk 1.04; 95% confidence interval (0.89-1.19); p = 0.58]. There were no between-group differences for secondary outcomes.
CONCLUSIONS: VPA added to the recommended strategy for adult GCSE is well tolerated but did not increase the proportion of patients hospital-discharged by day 15.
TRIAL REGISTRATION NO: NCT01791868 (ClinicalTrials.gov registry), registered: 15 February 2012.
参考来源
- Sharshar T, Porcher R, Asfar P, et al. Valproic acid as adjuvant treatment for convulsive status epilepticus: a randomised clinical trial. Crit Care. 2023. PMID: 36624526. doi:10.1186/s13054-022-04292-7
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。